Table 2.
Demographic and treatment patients' characteristics
| Number (%) | |
|---|---|
| Demographic characteristics | |
| Total | 66 |
| Boys | 45 (68%) |
| Risk group | |
| AR1 | 49 (74%) |
| AR2 | 17 (26%) |
| Age at maintenance therapy | |
| ≤6 years | 37 (56%) |
| >6 years | 29 (44%) |
| Genotypes, WT/ HT | |
| TPMT | 60 (90%)/6 (10%) |
| ITPA 94C > A | 56 (86%)/9 (14%) |
| ITPA IVS2 + 21A > C | 48 (74%)/17 (26%) |
| Treatment interruptions and toxicity | |
| Treatment interruptions | |
| 6-MP | 53 (75%) |
| MTX | 47 (83%) |
| Infections | |
| 0 | 16 (24%) |
| 1 to 3 episodes | 37 (56%) |
| 4 to 6 episodes | 13 (20%) |
| Hepatotoxicity | |
| 0 | 10 (15%) |
| 1 to 3 episodes | 22 (33%) |
| 4 to 6 episodes | 34 (52%) |
AR average risk, TMPT thiopurine S-methyltransferase, ITPA inosine triphosphate pyrophosphatase, WT wild-type, HT carrier of one variant allele, 6-MP 6-mercaptopurine, MTX methotrexate.